BioRestorative Therapies, Inc. (BRTX): Net earnings per share (EPS TTM)

BioRestorative Therapies (BRTX) develops cell-based therapies for intervertebral disc regeneration using patients' own tissues. The rolling trailing twelve-month earnings per share reflect the impact of zero sales and high capital expenditure. The -22.32 mark serves as a current indicator confirming that the securities' value depends on the future success of the ThermoStem platform and the scientific expertise of the management team.
Analytical breakdowns for BioRestorative (BRTX)

Comparing assets via earnings per share allows an investor to objectively assess capital generation efficiency. This metric is calculated as the ratio of net income to the total number of outstanding shares over a rolling year. For BioRestorative Therapies (BRTX), negative values reflect R&D expenditures and a reliance on external financing. Registration risks for discogenic pain therapy directly impact the dynamics of this indicator. By analyzing the change in EPS over 12 months, one can determine the business's development vector.